Decreased SCFA levels in EM patients, reduced inhibition of NF-κB, enhanced NLRP3 inflammasome activation, increased histone deacetylation (HDAC-1) promoting lesion growth. The gene discussed is NLRP3; the disease is erythema multiforme.